Vaxart's Upcoming Conference Calls: What You Need to Know
Vaxart, Inc. (OTCQX: VXRT) recently announced two significant upcoming conference calls, inviting stockholders and interested parties to join in as they present important company updates. These calls promise to shed light on the company's journey and current status as it navigates the complex world of biotechnology.
Third Quarter 2025 Financial Results
One of the highly anticipated events is the third quarter financial results conference call scheduled for November 13, 2025. During this call, which will commence at 4:30 p.m. ET, Vaxart’s senior management will discuss the company’s financial performance for the quarter ending September 30, 2025. This update will not only provide insights into the company’s financial health but also include a strategic overview of future direction.
Accessing the Conference Call
For those who wish to listen in on the live discussion, there will be various access options available. The direct webcast link will be provided, allowing individuals to join easily from their computers or mobile devices. Additionally, participants can dial in using the domestic number (877) 407-0832 or the international number (201) 689-8433 with conference ID 13756391 to engage in the talk.
Engaging with Stockholders
Following the financial results call, Vaxart will host a stockholder fireside chat on November 18, 2025, at 4:30 p.m. ET. This virtual gathering offers a platform for the senior management team to respond to frequently asked questions and share insights in a more informal setting. It highlights the company's commitment to maintaining open lines of communication with its investors.
How to Submit Questions
Vaxart encourages its investors to submit their questions before the conference call. By sending inquiries via email, stockholders can ensure their topics are covered. This proactive approach not only fosters transparency but also strengthens the relationship between the company and its stakeholders.
Replay Availability
For those unable to attend the live sessions, Vaxart plans to make recordings of the financial results and fireside chat easily accessible on its official website. This ensures that all interested parties can catch up on the valuable discussions at their convenience.
About Vaxart
Vaxart is navigating the innovative terrain of biotechnology as a clinical-stage enterprise. With a focus on developing oral recombinant vaccines using a proprietary delivery platform, Vaxart aims to revolutionize vaccine delivery methods. By utilizing pills that can endure storage and shipping conditions without refrigeration, Vaxart plans to mitigate the challenges associated with traditional vaccination methods such as needle-stick injuries.
The company is on an exciting path, developing oral vaccines targeting various viruses, including coronavirus, norovirus, and influenza. Furthermore, Vaxart is advancing a therapeutic vaccine for human papillomavirus (HPV), representing its entry into the immune-oncology arena.
With ambitious underlying patents filed both domestically and internationally, Vaxart is positioning itself at the forefront of vaccine innovation, ensuring their approach is both effective and user-friendly.
Frequently Asked Questions
When will Vaxart announce its financial results for Q3 2025?
The financial results for the third quarter of 2025 will be announced on November 13, 2025, with a corresponding conference call at 4:30 p.m. ET.
Where can I find the webcast for the conference calls?
The webcast for the conference calls will be available on Vaxart's official website, where participants can also submit questions prior to the call.
How can I submit questions for the management team?
Stockholders can submit their questions via email to Vaxart’s investor relations team in advance of the conference calls.
What is Vaxart's core focus in biotechnology?
Vaxart is focused on the development of oral recombinant vaccines intended to improve vaccine accessibility and safety, particularly through its innovative pill-based delivery system.
How does Vaxart protect its innovations?
Vaxart has filed extensive patent applications to safeguard its proprietary technology for oral vaccine delivery, aiming to cover both domestic and international markets.
